Literature DB >> 25304110

Biomarkers in hypertension and their relationship with myocardial target-organ damage.

Yang Xue1, Navaid Iqbal, Jeffrey Chan, Alan Maisel.   

Abstract

Essential hypertension is a very common health condition that is associated with an array of long-term end-organ diseases, including premature cardiovascular disease. Currently, there is no effective method to identify high-risk patients who may develop cardiovascular comorbidities in the future. Clinically, it would be beneficial to identify high-risk patients early in the disease process, so they can receive more aggressive blood pressure control and perhaps other specific disease-modifying therapies, thus delaying or avoiding the onset of cardiovascular disease. Cardiac biomarkers may have a unique role in the prognostic evaluation of patients with hypertension as many cardiac biomarker levels become abnormal long before the onset of overt cardiovascular disease. This review will provide an overview of cardiac biomarkers that may be used to predict future cardiovascular disease in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25304110     DOI: 10.1007/s11906-014-0502-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  68 in total

1.  Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

Authors:  Martin Magnusson; Stefan Jovinge; Erik Rydberg; Björn Dahlöf; Christian Hall; Olav W Nielsen; Anders Grubb; Ronnie Willenheimer
Journal:  Blood Press       Date:  2009       Impact factor: 2.835

2.  Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.

Authors:  Alan Maisel; Yang Xue; Kevin Shah; Christian Mueller; Richard Nowak; W Frank Peacock; Piotr Ponikowski; Martin Mockel; Christopher Hogan; Alan H B Wu; Mark Richards; Paul Clopton; Gerasimos S Filippatos; Salvatore Di Somma; Inder S Anand; Leong Ng; Lori B Daniels; Sean-Xavier Neath; Robert Christenson; Mihael Potocki; James McCord; Garret Terracciano; Dimitrios Kremastinos; Oliver Hartmann; Stephan von Haehling; Andreas Bergmann; Nils G Morgenthaler; Stefan D Anker
Journal:  Circ Heart Fail       Date:  2011-07-15       Impact factor: 8.790

3.  Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Authors:  Robb D Kociol; John R Horton; Gregg C Fonarow; Eric M Reyes; Linda K Shaw; Christopher M O'Connor; G Michael Felker; Adrian F Hernandez
Journal:  Circ Heart Fail       Date:  2011-07-08       Impact factor: 8.790

4.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

5.  N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis.

Authors:  Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima
Journal:  Circ Heart Fail       Date:  2012-10-02       Impact factor: 8.790

Review 6.  Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice.

Authors:  Toshinori Aoyagi; Taka-aki Koshimizu; Akito Tanoue
Journal:  Kidney Int       Date:  2009-08-19       Impact factor: 10.612

Review 7.  State of the art: using natriuretic peptide levels in clinical practice.

Authors:  Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2008-08-29       Impact factor: 15.534

Review 8.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

9.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

10.  Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients.

Authors:  Dike B Ojji; Lionel H Opie; Sandrine Lecour; Lydia Lacerda; Olusoji Adeyemi; Karen Sliwa
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.